Travere Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Travere Therapeutics

05/08/2025 24:25

Travere Therapeutics Inc TVTX.OQ TVTX.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The San Diego California-based  company is expected to report a 86.0% increase in revenue to $100.642 million from $54.12 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Travere Therapeutics Inc is for a loss of 30 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Travere Therapeutics Inc is $30.00, about 46.8% above its last closing price of $15.96

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.53
-0.54
-0.47
Beat
13.6
Dec. 31 2025
-0.54
-0.56
-0.73
Missed
-29.8
Sep. 30 2024
-0.69
-0.68
-0.70
Missed
-3​
Jun. 30 2024
-0.87
-0.86
-0.91
Missed
-5.7
​​Mar. 31 2024
-0.97
-0.99
-1.76
Missed
-77.6
Dec. 31 2023
-1.32
-1.27
-1.03
Beat
19.1​
Sep. 30 2023
-0.02
-0.14
-1.17
Missed
-719.7
Jun. 30 2023
-1.20
-1.14
-1.13
Beat
1

This summary was machine generated August 4 at 23:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)